Literature DB >> 2647492

Study of the arrangement of the functional domains along the yeast cytoplasmic aspartyl-tRNA synthetase.

G Prevost1, G Eriani, D Kern, G Dirheimer, J Gangloff.   

Abstract

Aspartyl-tRNA synthetase from yeast (AspRS) was screened for functional domains by measuring the effect of two types of amino acid mutations on its catalytic properties: (a) insertion of a dipeptide or a tetrapeptide along the polypeptide chain, (b) deletion of various lengths from the enzyme C-terminal. It was shown that insertion mutations significantly affect the kinetic properties of AspRS only when occurring in the second quarter of the molecule and the two centrally located mutations even inactivate the enzyme completely. Analysis of kinetic data strongly suggests that, in fact, all the observed activity modifications result from alteration of the activation reaction rate constant, kappa cat only. This led to the conclusion that the domain involved in aspartic acid activation should be located in the second quarter of the molecule. Furthermore, a deletion mutant with a modification of the last five amino acid residues was isolated. This mutant is fully active in the activation step, but has lost 80% of the wild-type aminoacylation activity. This involvement of the C-terminus in acylation implies that it has to be folded towards strategic regions of the enzyme, thus favouring conformations required for catalysis or maintaining the tRNA in a functional position.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647492     DOI: 10.1111/j.1432-1033.1989.tb14655.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Aspartyl-tRNA synthetase from Escherichia coli: cloning and characterisation of the gene, homologies of its translated amino acid sequence with asparaginyl- and lysyl-tRNA synthetases.

Authors:  G Eriani; G Dirheimer; J Gangloff
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

2.  Structure-function relationship of arginyl-tRNA synthetase from Escherichia coli: isolation and characterization of the argS mutation MA5002.

Authors:  G Eriani; G Dirheimer; J Gangloff
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

3.  Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity.

Authors:  Ryan J Taft; Adeline Vanderver; Richard J Leventer; Stephen A Damiani; Cas Simons; Sean M Grimmond; David Miller; Johanna Schmidt; Paul J Lockhart; Kate Pope; Kelin Ru; Joanna Crawford; Tena Rosser; Irenaeus F M de Coo; Monica Juneja; Ishwar C Verma; Prab Prabhakar; Susan Blaser; Julian Raiman; Petra J W Pouwels; Marianna R Bevova; Truus E M Abbink; Marjo S van der Knaap; Nicole I Wolf
Journal:  Am J Hum Genet       Date:  2013-05-02       Impact factor: 11.025

4.  Role of dimerization in yeast aspartyl-tRNA synthetase and importance of the class II invariant proline.

Authors:  G Eriani; J Cavarelli; F Martin; G Dirheimer; D Moras; J Gangloff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

5.  Using Gene Essentiality and Synthetic Lethality Information to Correct Yeast and CHO Cell Genome-Scale Models.

Authors:  Ratul Chowdhury; Anupam Chowdhury; Costas D Maranas
Journal:  Metabolites       Date:  2015-09-29

6.  Deinococcus glutaminyl-tRNA synthetase is a chimer between proteins from an ancient and the modern pathways of aminoacyl-tRNA formation.

Authors:  Marzanna Deniziak; Claude Sauter; Hubert Dominique Becker; Caroline Alexandra Paulus; Richard Giegé; Daniel Kern
Journal:  Nucleic Acids Res       Date:  2007-02-06       Impact factor: 16.971

7.  Genomic evolution of the pathogenic Wolbachia strain, wMelPop.

Authors:  Megan Woolfit; Iñaki Iturbe-Ormaetxe; Jeremy C Brownlie; Thomas Walker; Markus Riegler; Andrei Seleznev; Jean Popovici; Edwige Rancès; Bryan A Wee; Jennifer Pavlides; Mitchell J Sullivan; Scott A Beatson; Amanda Lane; Manpreet Sidhu; Conor J McMeniman; Elizabeth A McGraw; Scott L O'Neill
Journal:  Genome Biol Evol       Date:  2013       Impact factor: 3.416

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.